J&J buys eye disease gene therapy from MeiraGTx, giving the biotech the cash infusion it was seeking
Johnson & Johnson purchased a gene therapy for X-linked retinitis pigmentosa from MeiraGTx for $65 million upfront, the biotech announced Thursday.
The deal, which also comes with a commercial supply agreement, could be worth up to $415 million, including another $65 million in milestone payments expected in 2024 and up to $285 million upon first sales of the gene therapy in the US and EU.
J&J was already sponsoring a Phase III trial for the gene therapy candidate known as botaretigene sparoparvovec, or bota-vec for short. In 2019, J&J struck a licensing deal with MeiraGTx around three eye disease programs, including bota-vec, and paid $100 million upfront.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
